+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 99Years
All Genders
ID04902443

Evaluating Pomalidomide Combined with Nivolumab for Treating Adults with Virus-Associated Cancers Including HIV-Positive Individuals

Led by National Cancer Institute (NCI) · Updated on 2026-10-16

58

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are exploring new treatment options for cancers caused by viruses, such as Hodgkin and non-Hodgkin lymphoma, Kaposi sarcoma, and several others, aiming to find therapies that are both safer and more effective. This study focuses on evaluating the combination of two drugs, pomalidomide and nivolumab, to identify a safe dose and assess tolerability in adults with these virus-associated cancers, including those with HIV. The research is designed as a Phase I clinical trial to address the challenges of immune evasion by viruses in these malignancies. Participants will receive pomalidomide orally for 21 days in each 28-day cycle, for up to 24 cycles, while nivolumab will be given intravenously on day one of each cycle, except the first cycle when it is administered on day eight. Alongside these treatments, participants will take daily aspirin until 30 days after completing therapy. The study includes dose escalation and expansion phases to determine the optimal pomalidomide dose combined with a fixed dose of nivolumab. Treatment continues until disease progression, unacceptable toxicity, withdrawal, or investigator decision. Throughout the study, participants will undergo various assessments, including blood and urine tests, scans, physical exams, and functional status evaluations. They will maintain a pill diary and attend visits at the end of each cycle for monitoring and repeat tests. Additional sample collections such as saliva and optional biopsies may be performed. After treatment ends, follow-up visits occur monthly for 100 days, then by phone every three months for a year, and every six months thereafter, to monitor safety and anti-tumor activity. Participants with Kaposi sarcoma will have lesion photographs taken as part of the evaluation.

CONDITIONS

Brief Title

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Research Team

I

Irene B Ekwede, R.N.

R

Ramya M Ramaswami, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here